Increasing the Complement of Therapeutic Options in Bullous Pemphigoid

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Volume 78, Issue 2, Pages (July 2010)
Role of Angiogenic and Inflammatory Signal Pathways in Psoriasis
Jack L. Arbiser, Michael Y. Bonner 
Expanding Our Understanding of Human Skin Aging
Andrzej T. Slominski, Anna A. Brożyna, Robert C. Tuckey 
Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma
Michael L. Frisoli, John E. Harris 
Comparative Effectiveness Research
Takashi Hashimoto, Norito Ishii, Daisuke Tsuruta 
Clinical Snippets Journal of Investigative Dermatology
Antonio Julià  Journal of Investigative Dermatology 
Luigi Naldi  Journal of Investigative Dermatology 
Langerhans Cells Orchestrate TFH-Dependent Humoral Immunity
The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies  Anika Kasprick, Maike M. Holtsche,
Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari 
NRAS, NRAS, Which Mutation Is Fairest of Them All?
Clinical Snippets Journal of Investigative Dermatology
Research Techniques Made Simple: Cost-Effectiveness Analysis
Mechanisms of LtxA (Leukotoxin), a Potent New Anti-Inflammatory Agent for the Treatment of Alopecia Areata  Scott C. Kachlany  Journal of Investigative.
An Unexpected Role for TRPV4 in Serotonin-Mediated Itch
Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases  Megan H. Noe, Daniel B. Shin, Rebecca A. Hubbard,
Alexander Egeberg, Gregor B. E. Jemec, Alexa B
Modes of Action of Intravenous Immunoglobulin in Bullous Pemphigoid
Biologics and biomarkers for asthma, urticaria, and nasal polyposis
Post-IID 2008 International Meeting on Autoimmune Bullous Diseases
Tamar Nijsten  Journal of Investigative Dermatology 
Epitope-Dependent Pathogenicity of Antibodies Targeting a Major Bullous Pemphigoid Autoantigen Collagen XVII/BP180  Mayumi Wada, Wataru Nishie, Hideyuki.
Zika Virus Infection RIG-ged by Keratinocytes and Fibroblasts
Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?
More Than Many: How to Manage the Most Frequent Cancer?
Support Your Specialty
Clinical Snippets Journal of Investigative Dermatology
Minutes of the Board of Directors Meeting
Adalimumab in Psoriasis: How Much Is Enough?
Journal of Investigative Dermatology
Cancer Stem Cells in Squamous Cell Carcinoma
Star Trek Publishing Journal of Investigative Dermatology
IL-17 Takes Center Stage in Dermatophytosis
Clinical Snippets Journal of Investigative Dermatology
Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein 
Research Techniques Made Simple: Itch Measurement in Clinical Trials
Ryan P. Hobbs, Susan H. Smith, Spiro Getsios 
Journal of Investigative Dermatology
Journal of Investigative Dermatology
Journal of Investigative Dermatology 
Michael C. Velarde  Journal of Investigative Dermatology 
Society for Investigative Dermatology 2010 Meeting Minutes
Journal of Investigative Dermatology
Human Skin Explants Recapitulate Key Features of HSV-1 Infections
Staphylococcus epidermidis Sets Things Right Again
Erratum Journal of Investigative Dermatology
Research Snippets Journal of Investigative Dermatology
Dagmar Simon, Luca Borradori, Hans-Uwe Simon 
BJD Editor’s Choice Journal of Investigative Dermatology
Research Snippets from the British Journal of Dermatology
Cells to Surgery Quiz: February 2019
Journal of Investigative Dermatology
Research Snippets Journal of Investigative Dermatology
Journal of Investigative Dermatology
Hot on the Trail of Genes that Shape Our Fingerprints
Is complement a target for therapy in renal disease?
Journal of Investigative Dermatology
Journal of Investigative Dermatology
Releasing the Brakes on Cancer Immunotherapy
Paradoxical Effects of Sphingosine-1-Phosphate
Journal of Investigative Dermatology
Innate immune responses to infection
Complement disorders and hereditary angioedema
Innate Immunity Stimulates Permeability Barrier Homeostasis
Presentation transcript:

Increasing the Complement of Therapeutic Options in Bullous Pemphigoid Carolyn J. Kushner, Aimee S. Payne  Journal of Investigative Dermatology  Volume 138, Issue 2, Pages 246-248 (February 2018) DOI: 10.1016/j.jid.2017.09.026 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Mechanism of action of TNT003. TNT003 blocks classical pathway complement activation by binding C1s, leading to reduced production of inflammatory mediators (C3a, C4a, and C5a) as well as decreased C3c deposition, while sparing alternative and lectin complement activation pathways that can mediate innate immune defenses. Terminal complement blockade with the anti-C5 monoclonal antibody eculizumab inhibits the classical, alternative, and lectin pathways. Journal of Investigative Dermatology 2018 138, 246-248DOI: (10.1016/j.jid.2017.09.026) Copyright © 2017 The Authors Terms and Conditions